Larkspur Biosciences: Larkspur Biosciences kicks off with $30M+, hunting for new oncology immunotherapies

Based in Massachusetts, Larkspur Biosciences, a biotech focused on developing new immuno-oncology treatments, is now armed with $35.5 million in combined seed/Series A backing. The round, led by the Polaris Innovation Fund, 3E Bioventures Capital and Takeda's VC arm, will help fund development of new therapies for colorectal cancer. Larkspur...